Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters










Database
Language
Publication year range
1.
J Infect ; 58(3): 220-6, 2009 Mar.
Article in English | MEDLINE | ID: mdl-19217166

ABSTRACT

OBJECTIVES: Since levofloxacin at high doses was the best therapy in staphylococcal tissue-cage model of foreign-body infection, we hypothesized that moxifloxacin with higher ratio of area under the concentration-time curve to the MIC (AUC/MIC) would provide better results. METHODS: MICs, MBCs, MPCs (mutant prevention concentration) and 24h kill-curves were determined in the log and stationary phases. Using the aforementioned model, we tested the efficacy of levofloxacin 100mg/kg/d, moxifloxacin 40mg/kg/d and moxifloxacin 80mg/kg/d; they were equivalent to human levels for 1000mg/d, 400mg/d and 800mg/d, respectively. We screened for the appearance of resistant strains. RESULTS: MICs and MBCs in logarithmic and stationary phases and MPCs of levofloxacin were 0.5, 1 and 4, 0.8microg/ml, respectively, and those of moxifloxacin 0.12, 0.25 and 2, 0.25microg/ml. AUC/MIC were 234 (levofloxacin), 431 (moxifloxacin 40) and 568 (moxifloxacin 80). Bacterial counts decreases in tissue-cage fluids (means of logCFU/ml) were -1.81 (n=25), -1.31 (23), and -1.46 (20), respectively; for controls it was 0.24 (22). All groups were better than controls (p<0.05); no differences between them existed. CONCLUSIONS: Moxifloxacin with higher AUC/MIC ratio did not improve the efficacy of high doses of levofloxacin.


Subject(s)
Anti-Bacterial Agents/therapeutic use , Aza Compounds/therapeutic use , Foreign Bodies/complications , Levofloxacin , Ofloxacin/therapeutic use , Quinolines/therapeutic use , Staphylococcal Infections/drug therapy , Animals , Anti-Bacterial Agents/administration & dosage , Anti-Bacterial Agents/pharmacokinetics , Anti-Bacterial Agents/pharmacology , Aza Compounds/administration & dosage , Aza Compounds/pharmacokinetics , Aza Compounds/pharmacology , Fluoroquinolones , Male , Microbial Sensitivity Tests , Microbial Viability , Models, Animal , Moxifloxacin , Ofloxacin/administration & dosage , Ofloxacin/pharmacokinetics , Ofloxacin/pharmacology , Quinolines/administration & dosage , Quinolines/pharmacokinetics , Quinolines/pharmacology , Rats , Rats, Wistar , Time Factors
SELECTION OF CITATIONS
SEARCH DETAIL
...